Liang Gong

Dr. Liang Gong

Jiangnan University, Wuxi, Jiangsu, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
DLDan Li
Dan Li
LGLiang Gong
Liang Gong
HLHan Lin
Han Lin
SYSurui Yao
Surui Yao
YYYuan Yin
Yuan Yin
ZHzhaohui huang
zhaohui huang
Cell type-specific drug delivery is a straightforward strategy to achieve targeted cancer therapy and reduce side effects. Hyaluronic acid (HA), an U.S. Food and Drug Administration (FDA)-approved biocompatible carbohydrate polymer, has been extensively employed as a targeting ligand for a drug delivery system due to its natural ability to bind to tumor cells overexpressing cluster of differentiation 44 (CD44) receptors. Here, we report the preparation and antitumor efficacy of HA-coated bovine milk exosomes (HA-mExo) for tumor-specific delivery of microRNA-204-5p mimics (miR-204). The exosome-based delivery formulation was prepared with miR-204 encapsulated inside the lumen and HA displayed outside the membrane. The resultant formulation of HA-mExo-miR204 was able to specifically target CD44-positive cancer cells, with a concomitant increase in the intracellular uptake of miR-204. Compared to the uncoated mExo-miR204 formulation, HA-mExo-miR204 showed significantly increased antitumor efficacy both in vitro and in vivo. Importantly, HA-mExo-miR204 showed excellent biocompatibility and did not cause significant systemic toxicity. Given that both HA and bovine milk exosomes are low-cost and highly accessible biogenic materials with broad biomedical applications, HA-decorated bovine milk exosomes can be proven to be a practical drug delivery system of RNA drugs for targeted cancer therapy.

15 October 2021 in Small
Verified
Journal Article
Closed access
PDF file
LGLiang Gong
Liang Gong
YLYanchun Li
Yanchun Li
KCKaisa Cui
Kaisa Cui
YCYing Chen
Ying Chen
HHHaofei Hong
Haofei Hong
ZHzhaohui huang
zhaohui huang

17 November 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
LGLiang Gong
Liang Gong
LTLu Tian
Lu Tian
KCKaisa Cui
Kaisa Cui
YCYing Chen
Ying Chen
BLBingxin Liu
Bingxin Liu
ZHzhaohui huang
zhaohui huang

11 February 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
HHHaofei Hong
Haofei Hong
CLChen Li
Chen Li
LGLiang Gong
Liang Gong
JWJinfeng Wang
Jinfeng Wang
DLDan Li
Dan Li
ZWZhimeng Wu
Zhimeng Wu
Developing monoclonal antibodies (mAbs) for cancer immunotherapy is expensive and complicated. Nanobodies are small antibodies possessing favorable pharmacological properties compared with mAbs, but have limited anticancer efficacy due to the lack of an Fc region and poor pharmacokinetics. In this context, engineered universal endogenous antibody-recruiting nanobodies (UEAR Nbs), as a general and cost-effective approach, were developed to generate functional antibody-like nanobodies that could recapitulate the Fc biological functions for cancer immunotherapy. The UEAR Nbs, composed of the IgG binding domain and nanobody, were recombinantly expressed in E. coli and could recruit endogenous IgGs onto the cancer cell surface and trigger potent immune responses to kill cancer cells in vitro. Moreover, it was proved that UEAR Nbs displayed significantly improved half-lives in vivo. The in vivo antitumor efficacy of UEAR Nbs was demonstrated in a murine model using EGFR positive triple-negative breast cancer (TNBC).

19 February 2025 in Cell Reports
Verified
Journal Article
Open access
QZQiang Zhang
Qiang Zhang
KCKaisa Cui
Kaisa Cui
YKYue Kong
Yue Kong
JYJing Yu
Jing Yu
ZLZhanhao Luo
Zhanhao Luo
PLPing Lan
Ping Lan
C-Myc (Myc)-driven cancers exhibit aggressive phenotypes and therapeutic resistance. Here, integrating CRISPR-Cas9 screening, we identify dihydroorotate dehydrogenase (DHODH) as a promising target in Myc-driven cancer. Mechanistically, DHODH interacts with Myc to stabilize it independently of its enzymatic activity, thereby antagonizing SKP2-mediated polyubiquitination and proteasomal degradation. EN4, a Myc transcriptional activity inhibitor, disrupts DHODH-Myc interaction, promoting Myc degradation via SKP2. Additionally, Myc transcriptionally activates DHODH, enhancing pyrimidine biosynthesis and ferroptosis defense, processes dependent on DHODH enzymatic activity. Clinically, DHODH positively correlates with Myc, activating pyrimidine metabolism and ferroptosis defense in Myc-driven cancers. Hyperactivation of the DHODH-Myc axis is linked to colorectal cancer progression and poor prognosis. Therapeutically, combining EN4 with a DHODH enzymatic inhibitor demonstrates potent antitumor efficacy in Myc-driven colorectal cancer. Overall, our findings elucidate the metabolic and non-metabolic roles of DHODH in Myc-driven cancer, underscoring its dual potential as a therapeutic target addressing both enzymatic and non-enzymatic functions.

21 January 2022 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
YLYanchun Li
Yanchun Li
LGLiang Gong
Liang Gong
HHHaofei Hong
Haofei Hong
HLHan Lin
Han Lin
DLDan Li
Dan Li
ZWZhimeng Wu
Zhimeng Wu
A β-Galactosidase-dependent glycoengineering strategy was developed for cancer cell surface glycan imaging and target immunotherapy in high selectivity and efficacy.